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CB1 cannabinoid receptors (CB1) are located at axon terminals and effectively control synaptic communication and thereby circuit
operation widespread in the CNS. Although it is partially uncovered how CB1 activation leads to the reduction of synaptic excitation, the
mechanisms of the decrease of GABA release upon activation of these cannabinoid receptors remain elusive. To determine the mecha-
nisms underlying the suppression of synaptic transmission by CB1 at GABAergic synapses, we recorded unitary IPSCs (uIPSCs) at
cholecystokinin-expressing interneuron-pyramidal cell connections and imaged presynaptic [Ca2] transients in mouse hippocampal
slices. Our results reveal a power functionwith an exponent of 2.2 between the amplitude of uIPSCs and intrabouton [Ca2]. AlteringCB1
function by either increasing endocannabinoid production or removing its tonic activity allowed us to demonstrate that CB1 controls
GABA release by inhibiting Ca2 entry into presynaptic axon terminals via N-type (Cav2.2) Ca2 channels. These results provide
evidence for modulation of intrabouton Ca2 influx into GABAergic axon terminals by CB1 , leading to the effective suppression of
synaptic inhibition.
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Introduction
G-protein-coupled receptors (GPCRs), one of the largest protein
families coded in the genome (Bjarnado´ttir et al., 2006), are key
regulators of several neuronal functions, including the control of
synaptic communication (Hille, 1992). GPCR-dependent regu-
lation of synaptic transmission at axon terminals has been shown
to involve the opening of K channels, inhibition of Ca2 chan-
nels, blocking vesicle fusion, or the combination of these pro-
cesses (Miller, 1998; de Jong and Verhage, 2009).
CB1, one of themost abundant GPCRs in the CNS, is themain
receptor of endocannabinoids and the psychoactive ingredient of
marihuana (Zimmer et al., 1999; Wilson and Nicoll, 2001). This
presynaptic receptor potently affects circuit operation by reduc-
ing neurotransmitter release both at excitatory and inhibitory
synapses (Kreitzer and Regehr, 2001; Wilson et al., 2001; Brown
et al., 2004; Katona and Freund, 2008; Kano et al., 2009). It has
been demonstrated that glutamate release is effectively reduced
by CB1 activation in parallel with the suppression of Ca
2 influx
into cerebellar parallel fiber axon terminals (Kreitzer and Regehr,
2001; Zhang andLinden, 2009).However, the precisemechanism
of action is still controversial, because the reduction of Ca2
entry into boutons could be the consequence of either a direct
decrease of voltage-gated Ca2 channel function (Brown et al.,
2004) or an indirect effect through the opening of presynaptic K
channels (Daniel and Crepel, 2001; Daniel et al., 2004). In con-
trast, the mechanism underlying the reduction of inhibitory syn-
aptic transmission upon CB1 activation at single-bouton level is
still an open question. In this study, we combined electrophysio-
logical recordings with two-photon imaging to address this issue.
Materials andMethods
Slice preparation. CD1 or transgenic mice expressing DsRed fluorescent
protein under the control of the cholecystokinin promoter of either sex
(postnatal days 16–25) were used (CCK-BAC/DsRedT3 mouse line;
Ma´te´ et al., 2013). Horizontal hippocampal slices at 250 m thickness
were cut. Animals were anesthetized with isoflurane and decapitated in
accordancewith theHungarianAct ofAnimalCare andExperimentation
(1998, XXVIII, Section 243/1998), and with the ethical guidelines of the
Institute of Experimental Medicine Protection of Research Subjects
Committee. The brainswere quickly removed andplaced into an ice-cold
solution containing the following (in mM): sucrose 204.5, KCl 2.5,
NaHCO3 26, CaCl2 0.5, MgCl2 5, NaH2PO4 1.25, glucose 10, saturated
with 95% O2 and 5% CO2, pH 7.2–7.4. Hippocampal slices were pre-
pared using a Leica vibratome (Leica VT1200S; Leica Microsystems),
then transferred into an interface-type holding chamber filled with 36°C
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aCSF containing the following (in mM): NaCl 126, KCl 2.5, NaHCO3 26,
CaCl2 2,MgCl2 2, NaH2PO4 1.25, glucose 10, saturated with 95%O2 and
5% CO2, pH 7.2–7.4. Slices were kept up to 6 h in the holding chamber
before recordings. The same solutions were used during electrophysio-
logical and two-photon imaging experiments.
Electrophysiological recordings. Slices were transferred to a submerged
recording chamber. The flow rate was 2–3 ml/min. Experiments were
performed at room temperature under visual guidance. For electrophys-
iological recordings, an Olympus microscope (BX61WI) was used
equipped with a monochromator. DsRed in cells was excited at 488 nm
wavelength, and the resulting fluorescence was detected with a CCD
camera (TILL Photonics). Whole-cell patch-clamp recordings were
made using a Multiclamp 700B amplifier (Molecular Devices), traces
were filtered at 3 kHz, digitized at 10 kHz with a PCI-6024E board (Na-
tional Instruments), recorded with an in-house data acquisition and
stimulation software, and off-line analyzed using EVAN software (cour-
tesy of Istvan Mody, Department of Neurology, UCLA). Patch pipettes
were pulled (Zeitz Universal Puller, Zeitz-Instrumente Vertriebs) from
thin-walled borosilicate glass capillaries with an inner filament (1.5 mm
outer diameter, 1.17 mm inner diameter; Harvard Apparatus). Pipette
resistance was 5–7 M when filled with the intrapipette solution. For
recording interneurons the intrapipette solution contained the following
(inmM):K-gluconate 130,KCl 5,MgCl2 2, creatine phosphate 10,HEPES
10, Na2ATP 2, Na2GTP 1, and biocytin, 7. The solution also contained
100 M Fluo-5F (Invitrogen, KD 2.3 M). The pH was adjusted to 7.3,
the osmolarity was 290–300 mOsm. Interneurons were held between
60 and65mV (with 0 to250 pADCcurrent injections) and pairs of
action potentials (APs) at 10 Hz were evoked in every 30 s with 1.5–2 ms
long depolarizing (1–1.2 nA) current pulses. Presynaptic interneurons
were selected based on their DsRed content. The interneurons were sam-
pled from strata pyramidale, lucidum, and radiatum. The physiological
characteristics of interneurons were determined from their voltage re-
sponses to series of hyper- and depolarizing square current pulses of
800 ms duration and amplitudes ranging from 100 to 100 pA with
10 pA increments and to 500 pA with 50 pA increments. Intrapipette
solution used for the postsynaptic cell contained (in mM) 80 CsCl, 60
Cs-gluconate, 1 MgCl2, 2 Mg-ATP, 3 NaCl, 10 HEPES, 5 QX-314
[2(triethylamino)-N-(2,6-dimethylphenyl) acetamine] and 25 M Alexa-
Fluor 488, adjusted to pH 7.3 with CsOH. The osmolarity of the solution
was 295 mOsm. Unitary IPSCs (uIPSCs) were recorded in monosynap-
tically connected pyramidal cells that were voltage-clamped at the hold-
ing potential of65mV. Series resistance was frequently monitored and
65% compensation was applied. In paired recordings, similarly to the
imaging experiments, we waited 1 h to equilibrate the intrapipette solu-
tionwithin the cells. During this period, we obtained a stable recording in
a connected pyramidal cell. After 1 h, 40 uIPSCs were recorded as a
control period within 20 min, followed by the drug application. Drugs
were applied for 35 or 50 min and the values obtained during the last 20
min were used to compare with the values recorded in control condi-
tions. In addition, we performed control experiments in which either
BSA or aCSFwas appliedwithout any drug to reveal themagnitude of the
“rundown” during our experimental conditions. These control experi-
ments were randomly distributed throughout the whole experiment se-
ries and showed similar amplitude distribution and similar extent of
change in series resistance. Control experiments using DMSO were per-
formed in one block. On average, we found a rundown of 17.9 13.2%
(n  8) in control experiments for -Conotoxin GVIA (-CTx) treat-
ment, 15.3 35% (n 4) in controls for AM251 application, and 8.3
3.6% (n 8) in controls for carbachol (CCh) treatment, which was used
to correct the effects of drugs. DMSO applied at 0.01% caused a nonsig-
nificant change in the IPSC amplitude (11.4  11.2%, n  4; p  0.26,
paired t test). In addition, all experiments that showed50% rundown
during the control period (i.e., in the first 20 min) were discarded.
Two-photon imaging. For imaging experiments, the same stimulus and
experimental protocol was applied as in the electrophysiological record-
ings. Recording solutions were also identical, except that intrapipette
solution for imaging experiments contained 25 M AlexaFluor 594 (In-
vitrogen). Cells were visualized in slices using a Femto2D microscope
(Femtonics) equipped with oblique infrared illumination and a water-
immersion lens (25	, 1.05 NA, Olympus). Whole-cell recordings from
cholecystokinin (CCK)-immunopositive interneurons were performed
in current-clamp mode using a MultiClamp 700A amplifier. Electro-
physiological traces were filtered at 3 kHz and digitized on-line at 20 kHz.
Drugs were applied using a recirculation system with a peristaltic pump,
where the total volume was 6 ml and the solutions were equilibrated
with 95% O2 and 5% CO2. Two-photon imaging experiments were per-
formedwith a Femto2D laser-scanningmicroscope, using aMaiTai fem-
tosecond pulsing laser (SpectraPhysics) tuned to 810 nm. A detailed
description of the setup and calculation of G/Gmax values was described
previously (Holderith et al., 2012). Bouton-strings at 20–60mdepth in
the tissue and usually between 150 and 300 m from the soma were
selected preferentially at or near the stratum pyramidale in the CA3
region. There was no correlation between the distance of the bouton-
string from the soma and (1) the peak [Ca2]i, (2) decay of [Ca
2]i
transients, and (3) amplitude and SD of the AlexaFluor 594 fluorescent
signal. After 1 h loading period, a 20 min “control” scanning period was
performed during which10–15 boutons were scanned each two times
separated by 30 s. The same 20 min scanning period was repeated on the
same boutons after a 15 (for AM251, CCh, or 1 M -Conotoxin GVIA;
-CTx) or a 30 (for 1–50 nM -CTx) min drug equilibration period.
Transients derived from the two sequential scans were averaged for each
bouton. The recorded [Ca2]i transients were considered to originate
from boutons, if the [Ca2]i transient following filtering at 50 Hz
reached the peak within 18 ms after the action potential, and the signal
increased monotonically. If they passed this test, the peak of [Ca2]i
transients was determined with 200 Hz filtering and the largest value
within a time window of 2–8 ms after the action potential was used. The
amplitude of [Ca2]i transients went through a gradual decline during
the 1 h of imaging session in aCSF, therefore all drug effects were
normalized to their corresponding reduction obtained in aCSF. These
reductions controlling 1 M -CTx, 1–50 nM -CTx, 1–2 M AM251,
and CCh, were 18.4  4.7%, 16.3  4.4%, 10.5  14.1%, and 10.5 
14.1%, respectively. All data are normalized with these values except raw
traces. Control experiments were performed to show that 1 mg/ml BSA
together with 0.1%DMSO has no effect on the amplitude of the [Ca2]i
transients (p  0.27, paired t test). The 16.0  10.4% reduction of the
peak [Ca2]i in these experiments was similar to the 9.3 15.4% decre-
ment that was obtained in aCSF controls (p 0.62, unpaired t test). The
basal [Ca2]i level was alsomonitored before action potential initiations.
During drug applications the basal [Ca2]i levels were reduced by 8.8
46.4%, 12.0  22.9% and 23.5  29.4% in aCSF, AM251 and CCh,
respectively. There was no significant difference in either the basal
[Ca2]i level (p  0.18, ANOVA) or the change of it among different
experimental conditions (aCSF/AM251/CCh application, p  0.41,
ANOVA). The effects of AM251 and CCh did not depend on the basal
[Ca2]i level or the change of the basal [Ca
2]i level of boutons (p 0.3
for all Pearson correlations).
Immunohistochemistry. After recordings, slices were fixed in a fixative
containing 4% paraformaldehyde, 0.2% picric acid in 0.1 M phosphate
buffer (PB; pH 7.4) at 4°C at least for 12 h. Following the fixation, the
slices were washed in PB several times, embedded in agarose (2%) and
resectioned at 50–80 m thickness. Sections were washed with PB and
blocked in normal goat serum (10%), made up in Tris-buffered saline
(TBS; pH  7.4). CB1 was visualized using a rabbit or a guinea pig
anti-CB1 antibody (1:1000; Cayman Chemicals and Frontier Institute,
respectively) diluted in TBS containing 0.1% Triton X-100. Following
several washes in TBS, AlexaFluor 488-conjugated goat anti-rabbit IgG
(1:500; Jackson ImmunoResearch) or Dylight405-conjugated goat anti-
guinea pig (1:500, Jackson ImmunoResearch) was used to visualize the
CB1 immunoreaction, while Cy3-conjugated streptavidin (1:500–1:3000;
Invitrogen) was used to visualize the biocytin. Sections were then mounted
on slides in Vectashield (Vector Laboratories). Images were acquired using
Olympus FV1000 confocal microscope with either a 20	 or a 60	 oil-
immersion objective or with an AxioImager.Z1 using 40	 objective
(Zeiss). Cells identified as basket or mossy fiber-associated interneurons
based on their axonal arborizations were included in the analysis (Gulya´s
et al., 1993; Losonczy et al., 2004). Only CB1-immunopositive interneu-
rons were included in the study. Subsequently, some cells were further
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developed by immunoperoxidase reaction (ABC; Vector Laboratories)
using 3–3-diaminobenzidine tetrahydrochloride together with ammonium
nickel sulfate hexahydrate ((NH4)2(NiSO4)2*6H2O) (DAB-Ni) as a chro-
mogen. After dehydration and embedding inDurcupan, representative cells
were reconstructed with the aid of a drawing tube using a 40	 objective.
Drugs. -CTx (Tocris Bioscience, product no. 1085) stock was dis-
solved in distilled water and diluted to a final concentration in aCSF
together with 1 mg/ml BSA. AM251 (Tocris Bioscience, product no.
1117) was dissolved in DMSO to reach 10 mM stock solution, CCh (20
mM stock)was dissolved in distilledwater. All drugswere purchased from
Sigma-Aldrich unless indicated otherwise.
Data analysis and statistical tests. Two-photon imaging data and partly
the electrophysiological data were analyzed using MES (Femtonics).
Data were plotted usingOrigin 8.6 software. Statistical significance of the
drug effect was assessedwith Student’s paired t test for experiments using
-CTx and Wilcoxon signed rank test for experiments applying AM251
or CCh. Results were considered significant at p 
 0.05. Data are pre-
sented as mean SD unless indicated otherwise.
Calculation of the [Ca2]i–uIPSC relationship curve. First, dose–re-
sponse curves for -CTx were determined on [Ca2]i transients and
uIPSCs. The tested drug concentrations were 0.1, 1, 10, and 50 nM for
uIPSCs, and 1, 10, 50, and 1000 nM for [Ca2]i transients. Throughout
these experiments, 1 M AM251 was applied to avoid differential tonic
CB1 activation. By fitting the dose–response curves with a sigmoidal
function (f(x)  1/(1  (x/x0)
p)), the effect of 1 M -CTx on uIPSCs
and 0.1 nM-CTx on [Ca2]i transients could be estimated. Incorporat-
ing these two values into the measured dataset, a [Ca2]i–uIPSC rela-
tionship curve was constructed (see Fig. 2M ). Each point corresponds to
a given -CTx concentration (from left to right: 1000, 50, 10, 1, and 0.1
nM). Red data point shows the effect of tonic CB1 activity that is the
inverse of the AM251 effect. In other words, it corresponds to uIPSCs
amplitude and peak [Ca2]i transients in control condition, fromwhich
AM251 application enhanced the amplitudes to the 1:1 data point. We
calculated this point by taking the effects of AM251 in individual cells,
took their reciprocal values and calculated the average and SEM. Blue
Figure 1. The N-type voltage-gated Ca 2 channel blocker,-CTx suppresses both uIPSC amplitudes evoked by CB1-expressing interneurons in CA3 PCs and presynaptic [Ca
2] transients in a
dose-dependentmanner. Experimentswere performed in the presence of the CB1 antagonist, AM251 (1M).A, Representative experiments showing the changes in uIPSC amplitudes under control
conditions and upon bath application of 1 or 50 nM-CTx. Presynaptic action potentials (top traces) and concomitantly recorded uIPSCs (bottom traces; 10 individuals, gray; averages, black) are
shown. Numbers 1 and 2 indicate the period where traces from control and drug conditions were selected, respectively. B, Summary plots of normalized uIPSC amplitudes at three different
conditions. Error bars represent SD. The effect of 1 and 50 nM -CTx are statistically significant (paired t test, p
 0.05). C, Reconstruction of a representative CB1-immunolabeled basket cell
(dendrites, black; axons, red; s.p., stratum pyramidale; s.l., stratum lucidum). Scale bar, 100m. D, A biocytin-filled axon of a presynaptic interneuron is immunopositive for CB1. Scale bar, 5m.
E, Averages of 14–20 [Ca 2]i transientsmeasured at 7–10 boutons in a single cell in control conditions (black traces) and in the presence of 1 and 50 nM and 1M-CTx (red traces). Scale bars on
the right refer to each trace. Open symbols represent the amplitude of [Ca 2]i transients recorded from individual boutons of a representative cell. Filled symbols represent themean of individual
cells. All drug effects are statistically significant both at individual bouton levels and for individual cells (paired t test, p
 0.05). Mean SD are shown in red.
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symbol represents the effect of CCh normalized to control condition (to
the red point).
The relationship between [Ca2]i and uIPSC was estimated by fitting
it with a power function (f(x)  xm) using dataset from -CTx experi-
ments. Fitting the recorded data gave an exponent m  2.2. We per-
formed bootstrap analysis to validate that our experimental dataset size
was large enough for correct estimation of the fit, and calculate confi-
dence intervals. Bootstrap analysis resulted in an m value of 2.2  0.4.
Data points regarding CCh and AM251 application (see Fig. 2M, blue
and red symbols) fell inside the confidence intervals, therefore CCh and
AM251 effect were considered not significantly different from Ca2
channel blocking effect of -CTx.
Results
Here, we aimed to uncover how CB1 activation leads to the sup-
pression of GABAergic transmission in the hippocampus. As
a first step, we determined the relationship between action
potential-evoked [Ca2] transients in axon terminals ([Ca2]i)
of CCK and CB1-expressing perisomatic targeting interneurons
(basket and mossy fiber-associated cells) and the amplitude of
uIPSCs (Bucurenciu et al., 2010) recorded in CA3 pyramidal cells
(PCs). To eliminate the possible effects of differential tonic CB1
activation in slices, a CB1 antagonist (AM251, 1 M) was contin-
uously applied. Bath application of -CTx (a Cav2.2/N-type cal-
cium channel inhibitor) at different concentrations decreased the
uIPSC amplitudes (Wilson et al., 2001) in a dose-dependent
manner and fully blocked the postsynaptic response at concen-
trations 50 nM (Fig. 1A–D). In a separate set of experiments,
-CTx dose-dependently reduced [Ca2]i transients evoked by
single action potentials (Fig. 1E). Importantly, 1M-CTx com-
pletely eliminated the [Ca2]i transients, demonstrating that ac-
tion potential-evoked Ca2 entry into CB1-immunopositive
boutons is mainly, if not exclusively conducted via N-type Ca2
channels.
To reveal the relationship between Ca2 entry and subse-
quent transmitter release, we plotted the normalized uIPSC am-
plitudes as a function of normalized peak [Ca2]i obtained in
paired recordings and presynaptic Ca2 imaging, respectively
(Fig. 2). The plot was fitted with a power function with an expo-
nent of 2.2 (Fig. 2M), showing that a supralinear cooperativity of
Ca2 controls the GABA release from CCK axon terminals.
Next, we sought to reveal the mechanisms underlying the
suppression of inhibitory synaptic transmission by CB1. If CB1
activation reduces IPSC amplitude solely via the inhibition of
Ca2 entry, altering CB1 function should result in changes in the
corresponding [Ca2]i and uIPSC values in away that they ought
to fall onto the [Ca2]i-uIPSC curve derived from the -CTx
experiments. Alternatively, if these changes do not follow the
[Ca2]i-uIPSC relationship, additional mechanisms must play a
role. To address this issue, first we examined the effect of tonic
CB1 activation on uIPSCs. AM251 (1–2 M) application in-
creased the peak amplitude of uIPSCs in individual pairs to dif-
Figure 2. CB1 activation controls the amplitude of uIPSCs by altering presynaptic [Ca
2]i transients. A, AM251 (1M) application increases uIPSC amplitudes. B, Muscarinic receptor activation
by CCh (5M),which triggers endocannabinoid synthesis, results in a robust reduction in uIPSC amplitudes. C,D, Summary plots of the effects of AM251 and CCh on uIPSC peak amplitudes (changes
were significant;Wilcoxon signed rank test, p
 0.01). E–J, AM251 and CCh have opposite effects on the amplitude of presynaptic [Ca 2]i transients both at the levels of individual boutons (E,H ),
and of individual cells (I, J ). Mean SD is shown in red. The effects were statistically significant (Wilcoxon signed rank test, p
 0.05). K, L, Normalized values of the drug effects on peak uIPSC
amplitudes and on [Ca 2]i transients observed in AM251 and CCh. Mean SEM are shown.M, Relationship between normalized [Ca
2]i and uIPSC amplitude at different-CTx concentrations
(black; 1M, 50 nM, 10 nM, 1 nM, and 0.1 nMdata points from left to right) is shownand superimposed are the effects of CCh (blue) and tonic CB1 activation (inverse of AM251 effect: red; seeMaterials
and Methods). The curve was fitted by power function ( f(x) xm) with anm of 2.2. Error bars represent SEM.
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ferent extents (Fig. 2A,C), suggesting that there is a differential
tonic activation of the CB1 at these inhibitory synapses. Next, the
synthesis of endocannabinoids was augmented by bath applica-
tion of an acetylcholine receptor agonist (CCh; 5 M; Kim et al.,
2002; Makara et al., 2007). The drug treatment resulted in a sig-
nificant reduction in the peak amplitude of the uIPSCs (Fig.
2B,D), an effect that has been shown to be mediated via CB1 in
the CA3 region (Szabo´ et al., 2010). In parallel experiments, ac-
tion potential-evoked [Ca2]i transients were augmented by
AM251 and suppressed by CCh (Fig. 2E–J). Both AM251 and
CCh caused a more robust change in the uIPSC amplitudes than
in [Ca2]i (Fig. 2K,L). When we calculated the normalized
changes in uIPSC amplitudes and [Ca2]i, we found that the
obtained data points fell on the [Ca2]i-uIPSC curve (Fig. 2M).
These results indicate that CB1 activation reduces GABA release
by suppressing the Ca2 entry into presynaptic boutons via inhi-
bition of N-type voltage-gated Ca2 channel function.
Discussion
We have examined the cellular mechanisms underlying the sup-
pression of inhibitory synaptic transmission upon CB1 activation
in the CA3 region of acute hippocampal slices. Our principal
findings are as follows: (1) N-type voltage-gated Ca2 channels
are themain, if not the only source of the action potential-evoked
Ca2 entry into the boutons expressing CB1. (2) There is a supra-
linear cooperativity of intraboutonal [Ca2] and the GABA
release at CCK/CB1-positive GABAergic synapses. (3) CB1 can-
nabinoid receptors suppress GABA release via inhibition of
N-type voltage-gated Ca2 channel function.
Our measurements demonstrated that N-type voltage-gated
Ca2 channels mediated mainly, if not exclusively the action
potential-evokedCa2 entry intoGABAergic boutons expressing
CCK/CB1, in line with the previously proposed hypothesis (Wil-
son et al., 2001; Hefft and Jonas, 2005). Although Ca2 release
from intracellular Ca2 stores could contribute to the volume-
averaged [Ca2]i transients, as shown at cerebellar inhibitory
synapses (Llano et al., 2000), its magnitude may be low at stimu-
lus frequencies used in the present study (Carter et al., 2002). In
addition, spontaneous opening of N-type Ca2 channels at CB1-
expressing axon terminals can contribute also to the action
potential-independent GABA release (Goswami et al., 2012),
which could play a role in stabilizing synaptic function (Farrant
and Nusser, 2005).
Similar to other central synapses (von Gersdorff et al., 1998;
Fedchyshyn and Wang, 2005; Bucurenciu et al., 2010), at CCK-
expressing inhibitory perisomatic synapses the cooperativity of
Ca2 is supralinear, even though the GABA release is not as
tightly coupled to the opening of presynaptic Ca2 channels as in
parvalbumin-containing GABAergic axon terminals (Hefft and
Jonas, 2005; Bucurenciu et al., 2008). The obtained power coef-
ficient of 2.2 is somewhat greater than those determined for the
relationship between the presynaptic [Ca2] and the magnitude
of postsynaptic responses at parvalbumin-expressing inhibitory
synapses in the dentate gyrus (1.6) or at both auditory hair cell
and retinal ribbon synapses (1.1–1.4), but lower than that deter-
mined at young calyx of Held synapses (3; Eggermann et al.,
2012). Because N-type Ca2 channels are activated with high
efficacy by action potentials (Li et al., 2007), only a relatively
small number of channels located near the active zone should be
responsible for presynaptic Ca2 influx evoking GABA release at
CCK/CB1-expressing synapses (Eggermann et al., 2012).
We clarified that inhibition of N-type Ca2 channel function
is the main, if not the sole mechanism underlying the CB1-
mediated suppression of synaptic inhibition, which is in line with
a previous proposal based on data obtained in cell lines (Mackie
and Hille, 1992). By uncovering the detailed mechanisms of how
presynaptically located CB1 regulates transmitter release, we
open up new avenues leading to a better understanding how
endocannabinoids and 9dTHC exert their influence on the CNS.
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